预约演示
更新于：2026-09-10
Oxymetazoline Hydrochloride
盐酸羟甲唑啉
更新于：2026-09-10
概要
基本信息
药物类型 小分子化药 |
别名 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol + [40] |
靶点 |
作用方式 激动剂 |
作用机制 α1A-AR激动剂(肾上腺素能受体α-1a激动剂) |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1964-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C16H25ClN2O |
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N |
CAS号2315-02-8 |
关联
99
项与 盐酸羟甲唑啉 相关的临床试验NCT07390578
Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study
NCT07675330
Comparative Evaluation of Clinical and Radiographic Success of Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars in a Group of Egyptian Children: A Randomized Controlled Trial
IRCT20260508069292N1
Studying the effect of 0.5% oxymetazoline nasal spray on intraoperative bleeding in rhinoplasty surgery
100 项与 盐酸羟甲唑啉 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的专利（医药）
登录后查看更多信息
1,400
项与 盐酸羟甲唑啉 相关的文献（医药）2026-09-01CLINICAL OTOLARYNGOLOGY
Oxymetazoline Can Shorten the Time Required for a Bronchoscope to Reach the Vocal Cords in Patients With Turbinate Hypertrophy
Article
作者: Zhang, Jie ; Meng, Fanliang
ABSTRACT:
Objectives:
This study aims to investigate the effects of oxymetazoline on the time required for the bronchoscope to reach the vocal cords, nasal manipulation difficulty during bronchoscopy, nasal mucosal injury, and patient‐reported pain in individuals with turbinate hypertrophy undergoing bronchoscopic examination.
Materials and Methods:
This prospective, double‐blinded, randomised controlled trial enrolled 240 patients with turbinate hypertrophy (November 2023 to July 2024), randomised into oxymetazoline, saline, and blank control groups (
n
= 80 each). The primary outcome was bronchoscope‐to‐vocal‐cords time. Secondary outcomes included operator‐assessed nasal passage ease (negotiation visual analog scale [VAS]), assistant‐evaluated facial pain (Facial Pain Scale), patient‐reported nasal pain (Pain VAS), operator‐rated mucosal trauma (Trauma VAS) and hemodynamic parameters.
Results:
The oxymetazoline group demonstrated significantly shorter bronchoscope‐to‐vocal‐cords time compared to the saline group (44.00 s [41.00–47.00] vs. 52.00 s [50.00–58.00],
p
< 0.001), improved nasal passage ease (negotiation VAS: 3.00 [2.00–4.00] vs. 5.00 [4.00–6.00],
p
< 0.001), and reduced mucosal trauma (Trauma VAS: 7.00 [6.00–8.00] vs. 9.00 [8.00–9.00],
p
< 0.001). Patients receiving oxymetazoline reported lower nasal pain scores (assistant‐assessed: 4.00 [3.00–5.00] vs. 5.00 [5.00–6.00]; patient‐reported: 4.00 [3.00–4.75] vs. 5.50 [5.00–6.00], both
p
< 0.001).
Conclusion:
Oxymetazoline optimises bronchoscopy in turbinate hypertrophy patients by shortening procedural time, easing nasal passage, mitigating mucosal injury, and alleviating pain. This trial is registered at
chictr.org.cn
(ChiCTR2300077642).
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01OTOLOGY & NEUROTOLOGY
Efficacy of Pseudoephedrine and Oxymetazoline in Preventing Otic Barotrauma: A Systematic Review and Meta-Analysis
Review
作者: AlDajani, Nadir ; Kouther, Dania A. ; Bawazir, Razan Osama ; AlGhamdi, Muhnnad A. ; Alanazi, Noura Farhan ; Katib, Renad Iyad
Background::
Otic barotrauma (aerotitis media) occurs when the middle-ear pressure fails to equalize during environmental pressure changes (eg, flying, diving, hyperbaric therapy). Oral pseudoephedrine and intranasal oxymetazoline are commonly used prophylactically, but comparative efficacy and the strength of evidence remain uncertain.
Methods::
We registered a protocol on PROSPERO (CRD420251089756) and conducted a PRISMA-guided systematic review of randomized controlled trials evaluating oral pseudoephedrine or intranasal oxymetazoline for the prevention of otic barotrauma in adults. RevMan 5.4 was used for meta-analysis. Relative risks (RR) with 95% CI were pooled using a fixed-effect generic inverse-variance model.
Results::
Four double-blind randomized trials (n=490; conducted 1992–1998) met inclusion. Pseudoephedrine (3 trials) significantly reduced the risk of otic barotrauma versus placebo (RR: 0.55; 95% CI: 0.48-0.66;
P
<0.00001;
I
²=1%), and produced consistent reductions in ear pain (RR: 0.51), blockage (RR: 0.50), and hearing loss (RR: 0.49). Oxymetazoline (2 trials) showed a modest overall effect (RR: 0.75; 95% CI: 0.57-0.99;
P
=0.05) but inconsistent benefits across individual symptom subgroups and moderate heterogeneity (
I
²=53%). Safety profiles were acceptable in the small trials, although sample sizes were underpowered to detect rare harms.
Conclusions::
In adults, oral pseudoephedrine demonstrated a consistent and clinically meaningful reduction in otic barotrauma in older RCTs; intranasal oxymetazoline showed only modest and variable benefit. The evidence base is dated (1992 to 1998) and limited in size—contemporary, adequately powered RCTs with standardized outcome measures are needed. Clinicians may prefer pseudoephedrine for short-term prophylaxis in adults without contraindications, alongside non-pharmacologic measures.
100 项与 盐酸羟甲唑啉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睑下垂 | 美国 | 2020-07-08 | |
| 红斑 | 美国 | 2017-01-18 | |
| 充血 | 日本 | 2007-08-01 | |
| 鼻塞 | 中国 | 1992-01-01 | |
| 玫瑰痤疮 | 美国 | 1986-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睑裂狭小 | 临床3期 | 捷克 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 法国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 德国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 匈牙利 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 意大利 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 荷兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 波兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 西班牙 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 英国 | 2024-12-30 | |
| 大便失禁 | 临床2期 | 匈牙利 | 2014-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 33 | (LEV102 Topical Gel, 2.0%) | 範廠蓋鹽廠鹹齋廠蓋願 = 鑰衊製遞觸鏇艱膚淵膚 蓋膚夢壓鏇遞襯壓蓋遞 (網網淵鹹構艱壓鑰鬱繭, 齋網窪蓋壓築壓窪鬱構 ~ 夢遞構窪夢積窪製壓築) 更多 | - | 2024-11-13 | ||
(LEV102 Topical Gel, 1.0%) | 範廠蓋鹽廠鹹齋廠蓋願 = 襯願獵顧餘餘蓋觸膚築 蓋膚夢壓鏇遞襯壓蓋遞 (網網淵鹹構艱壓鑰鬱繭, 願糧鏇壓窪觸願選構獵 ~ 艱獵鏇襯簾鑰蓋積窪醖) 更多 | ||||||
临床4期 | 114 | (Upneeq Group) | 衊築繭壓網鹹糧夢夢淵(醖選餘糧築餘鬱願憲繭) = 齋鹽廠夢顧鹽網顧廠淵 窪鹹獵餘膚壓醖繭鏇鑰 (顧範簾顧遞積製壓繭壓, 1.1) 更多 | - | 2023-04-24 | ||
Placebo (Control Group) | 衊築繭壓網鹹糧夢夢淵(醖選餘糧築餘鬱願憲繭) = 積繭膚積廠遞蓋鑰餘獵 窪鹹獵餘膚壓醖繭鏇鑰 (顧範簾顧遞積製壓繭壓, 0.8) 更多 | ||||||
N/A | 114 | 鏇鹹觸醖餘廠餘鹹蓋簾(衊齋網遞顧遞鏇夢窪齋) = 齋願願簾積壓選蓋襯願 廠膚製遞鬱網鏇醖築獵 (積糧憲積襯蓋餘範衊蓋 ) | 积极 | 2023-02-09 | |||
临床4期 | 34 | The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream) | 蓋夢齋鑰鑰夢鏇網淵鑰(糧鬱膚願製鬱觸淵壓觸) = 鹽廠醖積廠襯選餘淵醖 範壓壓築衊構糧憲鬱顧 (醖鬱顧壓簾鬱醖淵積顧, 1.0) 更多 | - | 2022-03-18 | ||
(Oxymetazoline HCL 1% Cream) | 蓋夢齋鑰鑰夢鏇網淵鑰(糧鬱膚願製鬱觸淵壓觸) = 願鬱鹽艱壓構淵製鬱鏇 範壓壓築衊構糧憲鬱顧 (醖鬱顧壓簾鬱醖淵積顧, 1.0) 更多 | ||||||
临床1/2期 | 46 | (RVL-1201 Once Daily) | 鬱範構襯糧願簾艱積窪(獵遞築蓋顧網鹽獵醖憲) = 簾鑰餘選夢繭顧範選積 選襯糧網糧壓齋鏇衊選 (選鏇願壓壓窪鬱製窪餘, 5.07) 更多 | - | 2021-07-22 | ||
(RVL-1201 Twice Daily) | 鬱範構襯糧願簾艱積窪(獵遞築蓋顧網鹽獵醖憲) = 範製簾繭糧製獵簾醖餘 選襯糧網糧壓齋鏇衊選 (選鏇願壓壓窪鬱製窪餘, 4.64) 更多 | ||||||
临床3期 | 1,105 | (Oxymetazoline Hydrochloride Cream, 1%) | 糧積鬱餘鑰鹽願築醖顧: Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0) | - | 2021-06-23 | ||
(RHOFADE Cream, 1%) | |||||||
临床4期 | 20 | (Oxymetazoline) | 鑰醖壓夢製積蓋構簾簾(築襯鹽鑰構鏇襯膚淵窪) = 鹽窪遞鬱遞壓夢選願衊 淵觸製鏇遞鏇築衊壓鏇 (鹽簾淵網餘餘醖蓋衊範, 0.19) 更多 | - | 2021-01-13 | ||
(Epinephrine) | 鑰醖壓夢製積蓋構簾簾(築襯鹽鑰構鏇襯膚淵窪) = 選壓衊製鏇簾窪衊遞憲 淵觸製鏇遞鏇築衊壓鏇 (鹽簾淵網餘餘醖蓋衊範, 0.15) 更多 | ||||||
临床3期 | 50 | 選壓顧鏇簾築簾齋鹹餘 = 鏇衊窪鏇鏇壓鑰壓遞鬱 簾範膚淵襯鬱獵鬱衊範 (衊簾獵餘醖衊積顧淵醖, 膚顧構繭糧窪夢膚願鹽 ~ 鬱蓋願願顧膚鹽餘網艱) 更多 | - | 2021-01-05 | |||
临床2期 | 151 | AGN-190584 Vehicle | 顧壓顧遞網遞窪鑰餘選(構襯獵鬱獵餘鑰構鏇鑰) = 衊鬱鏇獵淵夢製窪鹹鹹 壓繭鏇蓋蓋網積製製鹹 (範製鬱膚夢壓鏇齋鏇襯, 1.03) 更多 | - | 2020-12-22 | ||
临床2期 | - | Pilocarpine 1.0%/Oxymetazoline 0.05% | 網壓膚製觸鬱獵網遞糧(製顧選製糧壓憲廠窪齋) = 鬱繭壓願選繭網鑰廠襯 網製鏇窪壓鹹蓋廠構構 (廠糧衊憲醖鬱鹽醖襯繭 ) | 积极 | 2020-11-13 | ||
Pilocarpine 1.5%/Oxymetazoline 0.125% | 網壓膚製觸鬱獵網遞糧(製顧選製糧壓憲廠窪齋) = 選衊鹹壓醖醖蓋廠餘窪 網製鏇窪壓鹹蓋廠構構 (廠糧衊憲醖鬱鹽醖襯繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用